APLIF News and Press, Appili Therapeutics Inc From 09/25/23

2023-09-25 09:47:15 ET The morning opened up on a high note for this dually-listed company as it announced U.S. Food and Drug Administration (FDA) approval of its Metronidazole Oral Suspension 500mg/5mL ( ATI-1501 ). Biopharma company %AppiliTherapeutics (TSX: $APLI) (OTCQB: $APLIF) foc...

FDA approves LIKMEZ as the brand name for Metronidazole Oral Suspension (LIKMEZ is a Trademark of Saptalis Pharmaceuticals, LLC) Currently LIKMEZ is the only liquid oral suspension of metronidazole approved in the U.S. Patent coverage provides drug market exclusivity through at ...

2023-08-11 17:45:32 ET Appili Therapeutics press release ( OTCQB:APLIF ): Q1 GAAP EPS of -C$0.01. As of June 30, 2023, the Company had cash of C$0.5 million, compared to C$2.5 million on March 31, 2023. In addition, the Company is dependent in large part on receiving the US$14...

FDA established a PDUFA action date for ATI-1501 of September 23, 2023 Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appi...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases a...

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), announced today a correction to its press release entitled “Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results” which was issued on June 23, 2023 (t...

2023-06-23 07:44:47 ET Appili Therapeutics press release ( OTCQB:APLIF ): FY GAAP EPS of -C$0.08. For further details see: Appili Therapeutics GAAP EPS of -C$0.08

Executed US$7.3M initial contract with U.S. Air Force Academy for ATI-1701 Upcoming PDUFA date of September 23, 2023 for ATI-1501 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on dru...

Upcoming PDUFA date of September 23, 2023 Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Pat...

Funding will enable Appili to advance it’s Biodefense Vaccine Candidate ATI-1701 to IND NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “...